Supplements aren’t magic pills. The FDA doesn’t stamp them as “safe” or “effective.” That’s a critical distinction most shoppers miss. Still, researchers keep finding weird little helpers in the dark.
Now melatonin might be one of them.
Alba Azola, MD, isn’t involved in the latest research, but she sees the potential. “I’m always excited when we find alternative Pain options that could potentially be helpful,” she says, emphasizing minimal side effects. It works as an adjunct. A support player. Especially for those whose sleep is shredded by chronic aches.
The Numbers Don’t Lie
This wasn’t just a guess. It was a systematic review and meta-Analysis. That’s fancy talk for looking at existing data until a pattern emerges.
23 trials. Over 2,001 participants. All suffering from chronic musculoskeletal pain. Low back issues, osteoarthritis, fibro, post-surgery agony. The researchers gathered randomized controlled trials— the gold standard. They normalized pain and sleep scores to a simple 0–100 scale. Zero meant fine. Hundred meant misery.
Some got the real deal. Others got placebo sugar pills. Or standard drugs. Doses varied wildly from 1 mg to 10 mg.
The outcome? Clearer than a bell.
Melatonin reduced chronic pain scores. It boosted sleep quality too. Kangchao Wu, the lead PhD student at the University of Syddney, didn’t mince words.
“The size of the pain-relieving effect Was comparable to conventional pain medicines like NSAIDs,” he notes.
NSAIDs include staples like acetaminophen, and ibuprofen
Let that sink in.
Breakdown of the Effects
Across all groups, melatonin knocked down pain scores by roughly 9 points. On that 100 point scale? That’s noticeable. Sleep quality jumped by 11 points.
But context matters.
Post-surgery pain relief? Marginal. Better than placebo, yes, but only by 2.5 to 5 points. Authors call it unlikely to matter much for most patients.
Here is the curveball: Duration matters more than dosage. Longer treatment showed better results. Not higher pills. Wu tried hard.
“We tried, but We didn’t find an optimal dose.”
More drug doesn’t mean less pain.
Side effects were mostly harmless. Nausea, dizziness, headaches, sleepiness. Temporary. No serious adverse events popped up.
Sleep Feeds the Beast
Why does this happen?
Daniel Clauw, MD from the University of Michigan, points to the sleep-pain loop. He wasn’t part of the study but knows the territory well. “Getting better and deeper Sleep is clearly important in Chronic Pain— especially nociplastic pain.”
It’s a cycle. Poor sleep hurts more. Less pain lets you sleep deeper.
Wu suggests two paths. One is indirect: Better sleep fixes mood, anxiety, activity levels. All that stuff feeds back into pain reduction. The other? Direct action.
Melatonin might act as an antioxidant or anti-inflammatory on its own. Modulating the pain signals directly. Who knew a sleep hormone had biceps?
The Caveats
Good data. Bad data exists too.
The review only looked at Randomized Controlled Trials. Smart. Focused specifically on musculoskeletal issues. Compared against both placebo and actual drugs. But certainty isn’t sky-high.
Pain findings were “low certainty.” Sleep quality was “moderate certainty.” Meaning? Future studies could shake this up. Trials were often small. Dosing was all over the map. Most folks weren’t tracked longer than three months.
So is it worth a try?
Clauw says yes for those with sleep issues and chronic pain. “Seems quite Safe and may be helpful.”
But don’t DIY without checking bases. Wu warns about interactions with other meds or conditions. Always ask a doc.
Start Low
Azola advocates patience. “Start low and Go Slow.”
One milligram is a common entry point. Bump it up only if necessary, aiming for a range of 3 to 6 mg generally.
More is not more when It comes to Melatonin.
Go past 10 mg and you might ruin sleep entirely. High doses can disrupt rest, creating a worse loop. Long term? Tolerance builds. It stops working.
Quality control is another beast. Supplements fly under the FDA’s regulatory radar before hitting shelves. Independent tests show many bottles don’t hold their labeled amount. Some are way off.
Check for third-party validation. Talk to your provider.
The data is promising. But the path isn’t simple yet.
